Table 1.

Clinical trials of tumor immunotherapy by using NK cells in recent years.

Cell source	Cancer type	Study phase	Trail Name	Ref
Not disclosed	Relapsed or refractory B cell non-hodgkin lymphoma	Early Phase I	NCT04639739	[47]
iPSC	Relapsed/refractory B-cell lymphoma; Chronic lymphocytic leukemia	Phase I	NCT04245722	[48]
iPSC	Relapsed/refractory acute myelogenous leukemia; Relapsed/refractory multiple myeloma	Phase I	NCT04614636	[49]
Peripheral blood	Acute myeloid leukemia; Myelodysplastic syndrome	Phase I	NCT04623944	[50]
iPSC	Ovarian cancer	Phase I	NCT04630769	[51]
iPSC	Advanced solid tumors	Phase I	NCT04551885	[52]
Peripheral blood	Relapsed/refractory non-hodgkin lymphoma; chronic lymphocytic leukemia; B cell acute lymphoblastic leukemia	Phase I	NCT05020678	[53]
Peripheral blood from HLA-haplo-identical donor	Refractory/relapsed B-cell NHL	Phase I	NCT04887012	[54]
Cord blood	Relapsed or refractory hematological malignancies	Phase I	NCT04796675	[55]
Not disclosed	Relapsed or refractory hematological malignancies	Phase I	NCT04796688	[56]
Not disclosed	Relapsed/refractory acute myeloid leukemia	Phase I	NCT05008575	[57]
Cord blood	Relapse/refractory hematological malignances	Phase I	NCT05092451	[58]
Not disclosed	Relapsed or refractory multiple myeloma	Early phase I	NCT05008536	[59]
Modified NK-92	Recurrent/metastatic gastric or head and neck cancer	Phase II	NCT04847466	[60]
Not disclosed	Relapsed/refractory B-cell acute lymphoblastic leukemia	Phase I	NCT05379647	[61]
iPSC	Relapsed/refractory CD19-positive B-cell malignancies	Phase I	NCT05336409	[62]
Not disclosed	Acute myeloid leukemia	Early phase I	NCT05215015	[63]
iPSC	Relapsed/refractory multiple myeloma	Phase I	NCT05182073	[64]
Not disclosed	Refractory metastatic colorectal cancer	Phase I	NCT05213195	[65]
Cord blood	Relapsed/refractory acute myeloid leukemia	Not Applicable	NCT05247957	[66]
Not disclosed	Advanced solid tumors	Early phase 1	NCT05194709	[67]